These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18242060)

  • 1. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storb RF
    J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
    Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
    Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
    Wang H; Yang YG
    Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
    Storb R; Gyurkocza B; Storer BE; Sorror ML; Blume K; Niederwieser D; Chauncey TR; Pulsipher MA; Petersen FB; Sahebi F; Agura ED; Hari P; Bruno B; McSweeney PA; Maris MB; Maziarz RT; Langston AA; Bethge W; Vindeløv L; Franke GN; Laport GG; Yeager AM; Hübel K; Deeg HJ; Georges GE; Flowers ME; Martin PJ; Mielcarek M; Woolfrey AE; Maloney DG; Sandmaier BM
    J Clin Oncol; 2013 Apr; 31(12):1530-8. PubMed ID: 23478054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.
    Akatsuka Y; Morishima Y; Kuzushima K; Kodera Y; Takahashi T
    Cancer Sci; 2007 Aug; 98(8):1139-46. PubMed ID: 17521316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.
    Bleakley M; Turtle CJ; Riddell SR
    Expert Rev Hematol; 2012 Aug; 5(4):409-25. PubMed ID: 22992235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review.
    Baron F; Storb R
    Springer Semin Immunopathol; 2004 Nov; 26(1-2):71-94. PubMed ID: 15549304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
    Hashimoto D; Merad M
    Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
    Hadjis AD; McCurdy SR
    Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.
    Ash S; Stein J; Askenasy N; Yaniv I
    Br J Cancer; 2010 Nov; 103(10):1597-605. PubMed ID: 20978501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
    Shimoni A; Nagler A
    Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.